Skip to main content
. Author manuscript; available in PMC: 2023 Feb 17.
Published in final edited form as: Mol Cancer Ther. 2021 Jun 22;20(9):1692–1701. doi: 10.1158/1535-7163.MCT-21-0210

Figure 2. MSU38225 decreases Nrf2 protein in cancer cells.

Figure 2.

A549 cells were treated with MSU38225 for 1–24 hours. The protein expression of Nrf2 was detected by western blotting (A) and quantified (B) using ImageJ. N=3 independent experiments. *, p<0.05 vs. DMSO control. C. The expression of Nrf2 protein was evaluated in both the cytosol and nucleus after treatment of MSU38225 for 24 hours in A549 cells. MCF7 cells were treated with (D) or without (E) tBHQ +/− MSU38225 and A549 cells (F) were treated with MSU38225 for 24 hours. Protein expression of Nrf2 and its downstream target NQO1 (D, E) or NF-κB family members, cyclinG1 and STAT3 (F) were detected by western blotting.